☆ 4.5 Letter

Tofacitinib for the treatment of refractory or glucocorticoid-dependent cutaneous leukocytoclastic vasculitis

DERMATOLOGIC THERAPY (2022)

Related references

Note: Only part of the references are listed.

Review Medicine, General & Internal

Diagnosis and management of leukocytoclastic vasculitis

Paolo Fraticelli et al.

Summary: Leukocytoclastic vasculitis is a type of small vessel vasculitis characterized by palpable purpura, which can be caused by various factors such as medications, infections, or malignancy. Diagnosis and treatment involve a comprehensive workup and symptom management, with appropriate therapy based on the underlying cause and severity of the condition.

INTERNAL AND EMERGENCY MEDICINE (2021)

Add to Collection

Letter Rheumatology

Tofacitinib for the treatment of antineutrophil cytoplasm antibody-associated vasculitis: a pilot study

Yun Liu et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Immunology

Tofacitinib Treatment of Refractory Cutaneous Leukocytoclastic Vasculitis: A Case Report

Kai-Jun Zhu et al.

Summary: This study presents a case of a 29-year-old woman with cutaneous leukocytoclastic vasculitis (CLV) who did not respond well to traditional treatments but showed improvement with short-term tofacitinib therapy. Tofacitinib may be a promising oral alternative for patients with CLV, but further clinical trials are needed to evaluate its efficacy and safety.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Letter Rheumatology